38029-16-2

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Hydroxy-2,6-di(hydroxymethyl)pyridine hydrochloride is used as an intermediate in the production of pyridoxine hydrochloride, which is a form of Vitamin B6. This vitamin plays a crucial role in various metabolic processes in the human body, including the synthesis of amino acids, neurotransmitters, and hemoglobin.
Used in Anti-tuberculosis Drug Production:
In the field of anti-tuberculosis drug development, 3-Hydroxy-2,6-di(hydroxymethyl)pyridine hydrochloride is utilized as a key component in the synthesis of effective medications targeting tuberculosis, a significant global health concern.
Used in Antihistamine and Sedative Production:
3-HYDROXY-2,6-DI(HYDROXYMETHYL)PYRRIDINE HYDROCHLORIDE also finds application in the creation of antihistamines and sedatives, which are essential in the treatment of allergies and sleep disorders, respectively.
Used in Food and Feed Additives:
3-Hydroxy-2,6-di(hydroxymethyl)pyridine hydrochloride is employed as a component in food and feed additives, contributing to the enhancement of nutritional value and ensuring the well-being of both humans and animals.
Used as a Dye Intermediate:
In the dye industry, 3-HYDROXY-2,6-DI(HYDROXYMETHYL)PYRRIDINE HYDROCHLORIDE serves as an intermediate in the production of various dyes, highlighting its versatility and applicability across different sectors.
Overall, 3-Hydroxy-2,6-di(hydroxymethyl)pyridine hydrochloride is a multifaceted chemical with applications spanning from healthcare to industrial processes, underlining its importance in modern chemical synthesis and production.

InChI:InChI=1/C7H9NO3/c9-3-5-1-2-7(11)6(4-10)8-5/h1-2,9-11H,3-4H2

Upstream product

• 109-00-2 3-HYDROXYPYRIDINE 
• 50-00-0 formaldehyd 
• 14187-25-8 3-hydroxy-2,6-bis(hydroxymethyl)pyridine hydrochloride 
• 1204311-38-5 C₄₄H₄₀N₈O₁₇ 
• 58958-50-2 methanol+acetone 

Downstream Products

• 14187-25-8 3-hydroxy-2,6-bis(hydroxymethyl)pyridine hydrochloride 
• 113231-32-6 3-hydroxy-2,6-pyridinedicarboxaldehyde 
• 910449-80-8 (12-benzyloxy-6,9-bis(methoxycarbonylmethyl)-3,6,9,15-tetraazabicyclo[9.3.1]-pentadeca-1⁽¹⁴⁾,11⁽¹⁵⁾,12-trien-3-yl)acetic acid, methyl ester of 
• 910449-77-3 3-benzyloxy-2,6-bis(bromomethyl)pyridine 
• 910449-81-9 (12-Benzyloxy-6,9-bis(carboxymethyl)-3,6,9,15-tetraazabicyclo[9.3.1]-pentadeca-1⁽¹⁴⁾,11⁽¹⁵⁾,12-trien-3-yl)acetic acid 
• 910449-79-5 12-benzyloxy-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1⁽¹⁵⁾,11,13-triene 
• 910449-78-4 12-benzyloxy-3,6,9-tris(2-nitrobenzenesulfonyl)-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1⁽¹⁵⁾,11,13-triene 
• 755692-12-7 3-benzyloxy-2,6-bis(hydroxymethyl)pyridine 
• 38199-60-9 12-(2-phenyl-4H-[1,3]dioxino[5,4-b]pyridin-6-yl)-dodecan-2-ol 
• 38199-55-2 triphenyl-(2-phenyl-4H-[1,3]dioxino[5,4-b]pyridin-6-ylmethyl)-phosphonium; chloride 
• 38324-61-7 2-phenyl-6-(11-tetrahydropyran-2-yloxy-dodec-1-enyl)-4H-[1,3]dioxino[5,4-b]pyridine 
• 38199-54-1 6-chloromethyl-2-phenyl-4H-[1,3]dioxino[5,4-b]pyridine 
• 113231-34-8 3-(Benzyloxy)-2,6-diformylpyridine bis 
• 227457-58-1 12-(4-Bromobenzyloxy)-3,6,9-tris(2-nitrobenzenesulfonyl)-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1⁽¹⁵⁾,11,13-triene 

Relevant academic research and scientific papers

Synthesis and biological activity of quaternary phosphonium salts based on 3-hydroxypyridine and 4-deoxypyridoxine

Methods for the synthesis of quaternary phosphonium salts based on 3-hydroxypyridine and 4-deoxypyridoxine were developed. Some of obtained compounds possess high antibacterial and antitumor activity in vitro.

Hydroxyl group effect in novel NNN type pyridine based ruthenium (II) complex for the transfer hydrogenation of ketones

The new NNN type pyridine ligands were prepared by using low cost and readily available starting materials and metalated with RuCl2(PPh3)3 to obtain ruthenium(II) complexes. All structures were illuminated by NMR, HRMS, and FT-IR spectroscopy. The complexes exhibited good catalytic activity in transfer hydrogen reaction of ketones and it was found that a hydroxyl group on β-position of the pyridine ring had a dramatic effect on the catalyst efficiency.

Lipophilic chelates and their use in imaging

The invention relates to chelate compounds which can be used in MRI, the chelates being intended to be conveyed by lipophilic transporters, such as lipid nanoparticles or liposomes. The invention also relates to compounds comprising, in association, these chelates and these transporters, if appropriate connected via chemical bonding groups, and to their use in diagnostic imaging, it being possible for this association additionally to comprise biological targeting markers, denoted biovectors.

The pyridinone-methide elimination

The quinone-methide elimination is a common, efficient methodology used in linkers designed to undergo self-fragmentation. Here, for the first time, we demonstrate this elimination in a pyridine ring system. Under physiological conditions, a compound cons

Synthesis of a novel amphiphilic GdPCTA-[12] derivative as a potential micellar MRI contrast agent

A novel amphiphilic contrast agent, a GdPCTA-[12] derivative containing a dodecyl chain as lipophilic moiety, has been prepared. A convergent synthetic route from commercially available diethylene triamine and 3-hydroxypyridine is described. The target amphiphilic gadolinium complex was obtained in nine steps in 22% overall yield. Physicochemical properties and relaxivity measurements of this new contrast agent are described.

Contrast agents for magnetic resonance imaging: A novel route to enhanced relaxivities based on the interaction of a Gd(III) chelate with poly-β-cyclodextrins

This study proposes a novel route to improved contrast agents for magnetic resonance imaging (MRI) applications based on the formation of a non-covalent adduct between a paramagnetic complex and an exogeneous macromolecule. For this purpose a 12-membered pyridine-containing triacerate macrocyclic ligand with a p-bromobenzyloxy substituent on the pyridine moiety was synthesized. The Gd(III) complex containing this ligand shows a relaxivity of 8.25mM-1S-1 at 20MHz and 25°C. The hydrophobic p-bromo- benzyloxy moiety promotes the interaction of the chelate with human serum albumin (HSA) (K(a) x 102M-1) and with β-cyclodextrin (K(a) = 8 x 102M- 1). Upon replacing β-cyclodextrin with a poly-β-cyclodextrin substrate (MW = ca. 6000 Da) a further relaxation enhancement is detected as a consequence of the increased molecular size of the resulting inclusion compound. In a typical experiment in blood serum, the observed relaxivity is 32mM-1S-1 (20 MHz, 25°C) when the concentrations are as follows: Gd(III) chelate I mM, poly-β-cyclodextrin 10mM, HSA 0.58mm. Under these conditions the Gd(III) chelate is mainly present as an inclusion compound with the poly-β-CD. This finding suggests a potential use for such a Gd(III) chelate/poly-β-CD system in MR angiographic applications. This study proposes a novel route to improved contrast agents for magnetic resonance imaging (MRI) applications based on the formation of a non-covalent adduct between a paramagnetic complex and an exogeneous macromolecule. For this purpose a 12-membered pyridine-containing triacetate macrocyclic ligand with a p-bromo-benzyloxy substituent on the pyridine moiety was synthesized. The GdIII complex containing this ligand shows a relaxivity of 8.25 mM-1 s-1 at 20 MHz and 25 °C. The hydrophobic p-bromo-benzyloxy moiety promotes the interaction of the chelate with human serum albumin (HSA) (Ka = 4×102 M-1) and with β-cyclodextrin (Ka = 8×102 M-1). Upon replacing β-cyclodextrin with a poly-β-cyclodextrin substrate (MW = ca. 6000 Da) a further relaxation enhancement is detected as a consequence of the increased molecular size of the resulting inclusion compound. In a typical experiment in blood serum, the observed relaxivity is 32 mM-1 s-1 (20 MHz, 25 °C) when the concentrations are as follows: GdIII chelate 1 mM, poly-β-cyclodextrin 10 mM, HSA 0.58 mM. Under these conditions the GdIII chelate is mainly present as an inclusion compound with the poly-β-CD. This finding suggests a potential use for such a GdIII chelate/poly-β-CD system in MR angiographic applications.

Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities

Symmetrically di-functionalized water soluble macrocyclic complexes of lanthanide, actinide and yttrium ions were obtained by metal templated, Schiff-base, cyclic condensation of: (1) a functionalized 1,2-diaminoethane and a dicarbonyl compound selected from the group consisting of 2,6-dicarbonylpyridine, 2,6-diformylpyridine, 2,5-dicarbonylfuran, 2,5-diformylfuran, 2,5-dicarbonyl-thiophene and 2,5-diformylthiophene; or (2) 1,2-diaminoethane and a ring-substituted heterocyclic dicarbonyl compound selected from a group consisting of substituted 2,6-dicarbonylpyridine, substituted 2,6-diformylpyridine, substituted 2,5-dicarbonylfuran, substituted 2,5-diformylfuran; substituted 2,5-dicarbonyl thiophene, and substituted 2,5-diformylthiophene. Asymmetrically functionalized water soluble macrocyclic complexes of the lanthanide, actinide and yttrium ions were obtained by metal templated, Schiff-base, cyclic condensation of appropriately substituted diamine and dicarbonyl precursors, with such precursors contributing two heteroaromatic moieties (pyridine, furan, thiophene, or a combination thereof) to the resulting macrocyclic structure. The coordination complexes thus formed are kinetically stable in dilute aqueous solution. They are further reacted, or coupled, through a substituent on the 1,2-diaminoethane or on the pyridine, furan, or thiophene moieties, to one of the following: proteinaceous materials, polysaccharides, polynucleotides, other biologically compatible macromolecules or bridging molecules which, can be further reacted or coupled to the above mentioned substrates. These macrocyclic complexes are suitable in the preparation of reporter molecules and for magnetic resonance, radiation imaging and radiation therapy.

Synthesis of 2,6-Diformyl-3-hydroxypyridine Bis: A Pentadentate N,N,N,N,N Ligand for the Preparation of Chelating Resins

The synthesis of 2,6-diformyl-3-hydroxypyridine bis as a versatile intermediate with a reactive hydroxyl group, which can be bonded to lipophilic chains and/or to polymeric supports, is reported.